ABCAM PLC Directorate Change (3922K)
December 13 2018 - 4:06AM
UK Regulatory
TIDMABC
RNS Number : 3922K
ABCAM PLC
13 December 2018
For immediate release
13 December 2018
ABCAM PLC
Appointment of Non-Executive Director
Abcam plc ("Abcam" or "the Company", AIM: ABC), a global leader
in the supply of life science research tools, is pleased to
announce the appointment of Giles Kerr as a non-executive Director
with effect from 12 December 2018.
Giles has extensive experience as an executive and non-executive
Director in a wide range of public and private organisations. He
recently stepped down as Finance Director of Oxford University, a
position he had held since 2005. He remains a non-executive
Director of Arix Biosciences plc, Adaptimmune Therapeutics plc,
Senior plc, PayPoint plc as well as Oxford Sciences Innovation.
From 1990 to 2004 Giles held a number of roles at Amersham plc,
including Group Finance Director. Giles is a graduate in Economics
from the University of York and a Chartered Accountant.
Peter Allen, Chairman of Abcam said: "I am delighted Giles is
joining the Board of Abcam. Giles brings a wealth of experience
within the life science sector, finance and a first-hand
understanding of our academic research customers. He will make a
valuable contribution to our Board."
Giles Kerr commented: "I have known and admired Abcam's business
for many years and am proud to be able to join the team. I look
forward to working with the Board as the Company continues to
execute on its strategy and build on its position as global
leader."
Giles will join the Audit & Risk Committee.
The composition of each of the Board Committees has also been
amended and is confirmed as follows:
Board Committee Membership
Nomination Committee Peter Allen (Chairman)
Louise Patten
Sue Harris
Mara Aspinall
=========================
Remuneration Committee Louise Patten (Chairman)
Peter Allen
Sue Harris
Mara Aspinall
=========================
Audit and Risk Committee Sue Harris (Chairman)
Peter Allen
Louise Patten
Giles Kerr
=========================
AIM Rules disclosures
Giles (age 59) holds or has held directorships in the five years
preceding his appointment at Abcam as follows:
Current directorships Previous Directorships
Arix Bioscience plc BTG plc
=============================
PayPoint plc Quanta Dialysis Technologies
=============================
Adaptimmune Therapeutics plc Victrex plc
=============================
Senior plc Elan Corporation
=============================
Oxford Sciences Innovation
=============================
Save as disclosed above there are no additional disclosures to
be made in accordance with Schedule Two paragraph (g) of the AIM
Rules.
For further information, please contact:
Abcam
+ 44 (0) 1223 696 000
Suzanne Smith, Chief Legal Officer and Company Secretary
James Staveley, VP, Investor Relations
J.P.Morgan Cazenove - Nominated Advisor & Corporate
Broker
+ 44 (0) 20 7742 4000
James Mitford
FTI Consulting
+ 44 (0) 20 3727 1000
Ben Atwell / Brett Pollard / Natalie Garland-Collins
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to
serve life science researchers globally to achieve their mission,
faster. Providing the research and clinical communities with tools
and scientific support, the Company offers highly validated
biological binders and assays to address important targets in
critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life
sciences, Abcam's ambition is to be the most influential company in
life sciences by helping advance global understanding of biology
and causes of disease, which, in turn, will drive new treatments
and improved health. Two-thirds of the world's 750,000 life science
researchers use Abcam's affinity binders, reagents, biomarkers and
assays and the Company's products are mentioned in over 20,000 of
the c.56,000 peer-reviewed papers published each year in the life
sciences.
By actively listening to and collaborating with researchers, the
Company continuously advances its portfolio to address their needs.
A transparent programme of customer reviews and datasheets,
combined with an industry-leading validation initiative, gives
researchers increased confidence in their results.
Abcam's eleven locations are in the world's leading life science
research hubs, enabling local services and multi-language support.
Founded in 1998 and headquartered in Cambridge, UK, the Company
sells to more than 130 countries. Abcam was admitted to AIM in 2005
(AIM: ABC).
To find out more, please visit www.abcam.com and
www.abcamplc.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAGMMMZGFFGRZM
(END) Dow Jones Newswires
December 13, 2018 05:06 ET (10:06 GMT)
Abcam (LSE:ABC)
Historical Stock Chart
From Apr 2024 to May 2024
Abcam (LSE:ABC)
Historical Stock Chart
From May 2023 to May 2024